Jim Cramer on Amgen: "The Biotech Really Impressed Me With a Very Strong Pipeline"

Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented:

With Amgen, I don’t know if you remember, at the JPMorgan Healthcare Conference, I heard a lot of good things. The biotech really impressed me with a very strong pipeline. That, plus good earnings, and maybe some good news about this weight loss drug, could send this Dow stock higher.

Amgen Inc. (NASDAQ:AMGN) delivers human therapeutics for conditions such as cancer, cardiovascular disease, osteoporosis, and autoimmune disorders. Cramer highlighted the company’s cholesterol drug during the November 12, 2025, episode and said:

We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why not go buy that?

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.